189 related articles for article (PubMed ID: 33760121)
1. linc‑ROR facilitates hepatocellular carcinoma resistance to doxorubicin by regulating TWIST1‑mediated epithelial‑mesenchymal transition.
Zhang Y; Wu W; Sun Q; Ye L; Zhou D; Wang W
Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760121
[TBL] [Abstract][Full Text] [Related]
2. CASC15 promotes epithelial to mesenchymal transition and facilitates malignancy of hepatocellular carcinoma cells by increasing TWIST1 gene expression via miR-33a-5p sponging.
Li Y; Chen G; Yan Y; Fan Q
Eur J Pharmacol; 2019 Oct; 860():172589. PubMed ID: 31401158
[TBL] [Abstract][Full Text] [Related]
3. ARK5 promotes doxorubicin resistance in hepatocellular carcinoma via epithelial-mesenchymal transition.
Xu T; Zhang J; Chen W; Pan S; Zhi X; Wen L; Zhou Y; Chen BW; Qiu J; Zhang Y; Yang Q; Feng X; Bai X; Liang T
Cancer Lett; 2016 Jul; 377(2):140-8. PubMed ID: 27126361
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of the long non-coding RNA SPRY4-IT1 promotes tumor cell proliferation and invasion by activating EZH2 in hepatocellular carcinoma.
Zhou M; Zhang XY; Yu X
Biomed Pharmacother; 2017 Jan; 85():348-354. PubMed ID: 27899259
[TBL] [Abstract][Full Text] [Related]
5. Effects of UPF1 expression on EMT process by targeting E‑cadherin, N‑cadherin, Vimentin and Twist in a hepatocellular carcinoma cell line.
Li Y; Zhang T; Qin S; Wang R; Li Y; Zhou Z; Chen Y; Wu Q; Su F
Mol Med Rep; 2019 Mar; 19(3):2137-2143. PubMed ID: 30628676
[TBL] [Abstract][Full Text] [Related]
6. Cx32 reverses epithelial-mesenchymal transition in doxorubicin-resistant hepatocellular carcinoma.
Yu M; Han G; Qi B; Wu X
Oncol Rep; 2017 Apr; 37(4):2121-2128. PubMed ID: 28260043
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-383 inhibits doxorubicin resistance in hepatocellular carcinoma by targeting eukaryotic translation initiation factor 5A2.
Tu C; Chen W; Wang S; Tan W; Guo J; Shao C; Wang W
J Cell Mol Med; 2019 Nov; 23(11):7190-7199. PubMed ID: 30801960
[TBL] [Abstract][Full Text] [Related]
8. Twist1-related miR-26b-5p suppresses epithelial-mesenchymal transition, migration and invasion by targeting SMAD1 in hepatocellular carcinoma.
Wang Y; Sun B; Zhao X; Zhao N; Sun R; Zhu D; Zhang Y; Li Y; Gu Q; Dong X; Wang M; An J
Oncotarget; 2016 Apr; 7(17):24383-401. PubMed ID: 27027434
[TBL] [Abstract][Full Text] [Related]
9. ZEB1 mediates doxorubicin (Dox) resistance and mesenchymal characteristics of hepatocarcinoma cells.
Long L; Xiang H; Liu J; Zhang Z; Sun L
Exp Mol Pathol; 2019 Feb; 106():116-122. PubMed ID: 30615851
[TBL] [Abstract][Full Text] [Related]
10. Knockdown of TWIST enhances the cytotoxicity of chemotherapeutic drugs in doxorubicin-resistant HepG2 cells by suppressing MDR1 and EMT.
Li R; Wu C; Liang H; Zhao Y; Lin C; Zhang X; Ye C
Int J Oncol; 2018 Oct; 53(4):1763-1773. PubMed ID: 30066890
[TBL] [Abstract][Full Text] [Related]
11. Circ_0003998 enhances doxorubicin resistance in hepatocellular carcinoma by regulating miR-218-5p/EIF5A2 pathway.
Li X; He J; Ren X; Zhao H; Zhao H
Diagn Pathol; 2020 Dec; 15(1):141. PubMed ID: 33308276
[TBL] [Abstract][Full Text] [Related]
12. Twist1 Regulates Vimentin through Cul2 Circular RNA to Promote EMT in Hepatocellular Carcinoma.
Meng J; Chen S; Han JX; Qian B; Wang XR; Zhong WL; Qin Y; Zhang H; Gao WF; Lei YY; Yang W; Yang L; Zhang C; Liu HJ; Liu YR; Zhou HG; Sun T; Yang C
Cancer Res; 2018 Aug; 78(15):4150-4162. PubMed ID: 29844124
[TBL] [Abstract][Full Text] [Related]
13. NSC 74859 enhances doxorubicin cytotoxicity via inhibition of epithelial-mesenchymal transition in hepatocellular carcinoma cells.
Hu QD; Chen W; Yan TL; Ma T; Chen CL; Liang C; Zhang Q; Xia XF; Liu H; Zhi X; Zheng XX; Bai XL; Yu XZ; Liang TB
Cancer Lett; 2012 Dec; 325(2):207-13. PubMed ID: 22781398
[TBL] [Abstract][Full Text] [Related]
14. Propofol inhibits proliferation, migration, and invasion of hepatocellular carcinoma cells by downregulating Twist.
Zheng H; Fu Y; Yang T
J Cell Biochem; 2019 Aug; 120(8):12803-12809. PubMed ID: 30861184
[TBL] [Abstract][Full Text] [Related]
15. Knockdown of eukaryotic translation initiation factor 5A2 enhances the therapeutic efficiency of doxorubicin in hepatocellular carcinoma cells by triggering lethal autophagy.
Tang Y; Chen K; Luan X; Zhang J; Liu R; Zheng X; Xie S; Ke H; Zhang X; Chen W
Int J Oncol; 2020 Dec; 57(6):1368-1380. PubMed ID: 33174013
[TBL] [Abstract][Full Text] [Related]
16. Long non‑coding RNA H19 is involved in sorafenib resistance in hepatocellular carcinoma by upregulating miR‑675.
Xu Y; Liu Y; Li Z; Li H; Li X; Yan L; Mao J; Shen J; Chen W; Xue F
Oncol Rep; 2020 Jul; 44(1):165-173. PubMed ID: 32627034
[TBL] [Abstract][Full Text] [Related]
17. lncRNA-POIR promotes epithelial-mesenchymal transition and suppresses sorafenib sensitivity simultaneously in hepatocellular carcinoma by sponging miR-182-5p.
Chen BW; Zhou Y; Wei T; Wen L; Zhang YB; Shen SC; Zhang J; Ma T; Chen W; Ni L; Wang Y; Bai XL; Liang TB
J Cell Biochem; 2021 Jan; 122(1):130-142. PubMed ID: 32951268
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
19. Linc-ROR drive adriamycin resistance by targeting AP-2α/Wnt/β-catenin axis in hepatocellular carcinoma.
Shi CJ; Lv MY; Deng LQ; Zeng WQ; Fu WM; Zhang JF
Cell Biol Toxicol; 2023 Aug; 39(4):1735-1752. PubMed ID: 36576707
[TBL] [Abstract][Full Text] [Related]
20. lncRNA DQ786243 promotes hepatocellular carcinoma cell invasion and proliferation by regulating the miR‑15b‑5p/Wnt3A axis.
Lin Z; Liu J
Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
